KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $12.3 million.

  • CRISPR Therapeutics AG's Non-Current Deffered Revenue changed 0.0% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $12.3 million for FY2024, which is 1205.4% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Non-Current Deffered Revenue is $12.3 million, which was down 0.0% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Non-Current Deffered Revenue ranged from a high of $15.8 million in Q3 2023 and a low of $11.8 million during Q2 2021
  • For the 5-year period, CRISPR Therapeutics AG's Non-Current Deffered Revenue averaged around $12.6 million, with its median value being $12.3 million (2021).
  • In the last 5 years, CRISPR Therapeutics AG's Non-Current Deffered Revenue surged by 2840.22% in 2023 and then tumbled by 2211.97% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Non-Current Deffered Revenue stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then grew by 13.71% to $14.0 million in 2023, then decreased by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
  • Its Non-Current Deffered Revenue stands at $12.3 million for Q3 2025, versus $12.3 million for Q2 2025 and $12.3 million for Q1 2025.